For the Inventor, By the Inventor

Enter assignee name

Frankfurt, Germany

Zentaris Gmbh

USPTO Granted Patents = 22

% Expired Patents = 54.5

CIPO Patents = 1

Trademarks = 2

Forward Citations = 204

Loading Chart...

Loading Chart...

61 inventors (with patents filed for the assignee):

Eckhard Günther (7 out of 23 patents)

Bernhard Kutscher (7 out of 45 patents)

Thomas Reissmann (5 out of 16 patents)

4. Tilmann Schuster (4 out of 14 patents)

5. Horst Bauer (3 out of 5 patents)

6. Peter Romeis (3 out of 4 patents)

7. Bernd Nickel (3 out of 27 patents)

8. Peter Emig (3 out of 29 patents)

9. Jürgen Schmidt (3 out of 5 patents)

10. Silke Baasner (2 out of 11 patents)

11. Jean Martinez (2 out of 22 patents)

12. Matthias Rischer (2 out of 9 patents)

13. Thomas Beckers (2 out of 36 patents)

14. Jurgen Engel (2 out of 81 patents)

15. Irene Seipelt (2 out of 13 patents)

22 patents: Sort by Forward Citations

1. 8937068 - Pyridopyrazine derivatives and their use (2015-01-20),

2. 8710089 - Triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors (2014-04-29),

3. 8669091 - Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof (2014-03-11),

4. 8217042 - Pyridopyrazines and their use as modulators of kinases (2012-07-10),

5. 7884071 - Administration form for pharmaceutically active peptides with sustained release and method for the production thereof (2011-02-08),

6. 7871977 - Process for producing sterile suspensions of slightly soluble basic peptide complexes, sterile suspensions of slightly soluble basic peptide complexes, pharmaceutical formulations containing them, and the use thereof as medicaments (2011-01-18),

7. 7829724 - Triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors (2010-11-09),

8. 7732412 - Methods of treatment using novel LHRH antagonists having improved solubility properties (2010-06-08),

9. 7214662 - Injectable solution of an LHRH antagonist (2007-05-08),

10. 7211588 - N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation (2007-05-01),

11. 7205299 - Indole derivatives having an apoptosis-inducing effect (2007-04-17),

12. 7148195 - LHRH antagonists having improved solubility properties (2006-12-12),

13. 7087214 - Water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases (2006-08-08),

14. 7056912 - Heteroaryl derivatives and their use as medicaments (2006-06-06),

15. 7026310 - Heteroaryl derivatives and their use as medicaments (2006-04-11),

Company Overview

Zentaris GmbH is a biopharmaceutical company based in Frankfurt, Germany, specializing in the development of innovative therapeutics for the treatment of cancer and endocrine disorders. The company focuses on advancing its proprietary drug candidates through clinical development, leveraging its expertise in drug formulation and delivery. Zentaris is committed to addressing unmet medical needs by harnessing cutting-edge research and technology in the biopharmaceutical sector, aiming to improve patient outcomes globally.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

22 Patents

#41 in Frankfurt

#2,061 in Germany

#28,749 in the World

Frankfurt, Germany

Zentaris Gmbh

Forward Citations = 204

61 inventors:

Eckhard Günther (7 out of 23 patents)

Bernhard Kutscher (7 out of 45 patents)

Thomas Reissmann (5 out of 16 patents)

4. Tilmann Schuster (4 out of 14 patents)

5. Horst Bauer (3 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Zentaris Gmbh. Retrieved from https://idiyas.com/company/zentaris

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…